Core Viewpoint - The company has approved the temporary use of idle raised funds to supplement working capital, with specific amounts and timeframes outlined in multiple announcements [1][2][3]. Group 1: Fund Usage Approvals - On December 3, 2024, the company approved the use of up to 400 million yuan of idle raised funds for temporary working capital, with a usage period not exceeding 12 months [1]. - On December 30, 2024, the company approved the use of up to 300 million yuan of idle raised funds for temporary working capital, with a similar usage period [2]. - On May 20, 2025, the company approved the use of up to 80 million yuan of idle raised funds for temporary working capital, also with a maximum usage period of 12 months [3]. Group 2: Fund Return Status - As of the latest updates, 30 million yuan from the 400 million yuan approved on December 3, 2024, has been returned to the dedicated fundraising account, with 370 million yuan remaining [3]. - From the 300 million yuan approved on December 30, 2024, 295 million yuan remains unreturned [3]. - The 80 million yuan approved on May 20, 2025, has not yet been utilized, totaling 665 million yuan of idle raised funds that will be returned before the expiration date [3].

Group 1 - The company held its 17th meeting of the 8th Supervisory Board on May 23, 2025, with three supervisors present, and the meeting was legally valid [1] - The Supervisory Board approved the proposal to temporarily use part of the idle raised funds to supplement working capital, which is expected to enhance the efficiency of fund usage and reduce financial costs [2] - The company is authorized to use up to RMB 400 million of idle raised funds for a period not exceeding 12 months from the date of approval by the Board, without affecting the normal operation of the investment projects [2]

Core Viewpoint - The company plans to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the normal operation of its fundraising investment projects [1][6][7]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue 20 million convertible bonds at a face value of RMB 100 each, raising a total of RMB 200,000 million, with a net amount of RMB 1,986,231,480.13 after deducting issuance costs [1][2]. Fundraising Usage Situation - As of April 30, 2025, the company has used RMB 149,377.31 million of the raised funds, with a remaining balance of RMB 4,777.25 million [2][3]. Previous Use of Idle Funds - The company previously approved the use of up to RMB 45,000 million of idle funds to supplement working capital, with a usage period not exceeding 12 months [3][4]. Current Plan for Using Idle Funds - The company plans to use up to RMB 40,000 million of idle funds to supplement working capital, with a similar 12-month usage period, aiming to improve fund efficiency and reduce financial costs [5][6]. Reasonableness and Necessity of Current Plan - The company justifies the use of idle funds by the increasing demand for working capital due to its expanding operations, estimating a potential savings of approximately RMB 12.4 million in financial costs [6][7]. Review Procedures and Opinions - The board and supervisory committee have approved the plan, confirming that it meets legal requirements and does not affect the normal operation of fundraising investment projects [7][8].

Core Viewpoint - The company intends to temporarily use part of the idle raised funds to supplement its working capital, ensuring that this does not affect the normal progress of the fundraising investment projects [1][4][6] Summary of Fundraising Situation - The company issued 2,430,000 convertible bonds at a price of 100 yuan each, raising a total of 243 million yuan, with a net amount of approximately 238.63 million yuan after deducting issuance costs [1] - The funds have been deposited in a dedicated account, and a tripartite supervision agreement has been signed with the sponsoring institution and the bank [1] Summary of Investment Projects and Idle Funds - The total investment for the projects is 250 million yuan, with 243 million yuan planned to be used from the raised funds [2] - Due to the construction cycle of the investment projects, some funds are temporarily idle, and the company plans to use these idle funds for working capital without changing the purpose of the raised funds [2][5] Previous Use of Idle Funds - The company previously used 51.8 million yuan of idle funds to supplement working capital, which has been fully returned to the dedicated account within the stipulated 12 months [3] Current Plan for Using Idle Funds - The company plans to use up to 60 million yuan of idle funds for working capital, with a usage period not exceeding 12 months from the board's approval date [4][5] Approval Process - The board of directors and the supervisory board have approved the use of idle funds, confirming that it will not affect the investment projects and complies with relevant regulations [5][6]

Core Viewpoint - The company plans to temporarily use idle raised funds to supplement working capital, ensuring that it does not affect the construction of fundraising projects and normal use of funds [6][11]. Fundraising Basic Situation - The company was approved to issue 60.01 million A-shares at a price of 16.24 yuan per share, raising a total of approximately 974.56 million yuan [1]. - The net amount raised after deducting issuance costs was approximately 879.45 million yuan, with excess funds amounting to approximately 273.77 million yuan [3]. Fundraising Investment Project Basic Situation - The total investment amount for the projects is approximately 605.68 million yuan, all of which is funded by the raised funds [3]. - The company has approved a change in the use of part of the raised funds, allocating 45 million yuan for the "Marketing Network Construction Project" to acquire 60% of the shares in Zhoushan Likang Pharmaceutical Chain Co., Ltd. [4]. Previous Use of Idle Raised Funds - The company previously used 150 million yuan of idle raised funds to supplement working capital, which has been fully returned to the fundraising account within the stipulated period [6][11]. Current Use of Idle Raised Funds - The company plans to use up to 100 million yuan of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [6][7]. - This use is limited to operations related to the main business and will not be used for stock trading or other non-operational purposes [7]. Necessity and Reasonableness - The decision to use idle funds is aimed at reducing financial costs and supporting the company's operational needs, thereby enhancing its competitiveness in the pharmaceutical health sector [7][9]. Internal Decision-Making Procedures - The board of directors, supervisory board, and independent directors have all approved the use of idle funds, confirming compliance with relevant regulations [8][9][11].

股票代码：002728 股票简称：特一药业 公告编号：2025-033 特一药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 5 月 资金暂时补充流动资金的议案》，现就使用可转债部分闲置募集资金暂时补充流动资金 的相关事宜公告如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可20172004 号文《关于核准特一药业集团股份 有限公司公开发行可转换公司债券的批复》核准，公司获准于 2017 年 12 月 6 日向社会 公开发行 3,540,000 张可转换公司债券，每张面值 100 元，发行总额 354,000,000.00 元。 公司发行可转债募集资金总额为人民币 354,000,000.00 元，利息为 12,776.67 元， 扣除承销费用、保荐费人民币 6,000,000.00 元后的发行金额 348,012,776.67 元，已由 保荐人（主承销商）于 2017 年 12 月 12 日汇入本公司募集资金专项存储账户内。另扣 除律师、会计师、资信评 ...

股票代码：002728 股票简称：特一药业 公告编号：2025-032 特一药业集团股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特一药业集团股份有限公司（以下简称"公司"）第五届监事会第二十八次会议于 以通讯或书面方式发出。会议应出席监事 3 名，实际出席监事 3 名，会议的召集、召开 符合《公司法》和《公司章程》规定。 会议由公司监事会主席张名坚先生主持。与会监事审议了有关议案，一致通过以下 决议： 一、审议通过《关于使用可转债部分闲置募集资金暂时补充流动资金的议案》 （表决结果：同意票 3 票，反对票 0 票，弃权票 0 票） 二、审议通过《关于使用非公开发行部分闲置募集资金暂时补充流动资金的议案》 公司已归还前次使用非公开发行部分闲置募集资金暂时补充流动资金的募集资金。 监事会同意公司在保证 2021 年非公开发行股票募集资金投资项目的资金需求前提下使 用 不 超 过 人 民 币 1,500 万 元 （ 占 公 司 2021 年 非 公 开 发 行 股 票 募 集 资 金 净 额 董事会第三十二次会议审议通过后，自首次办理暂时补充流动 ...

Core Points - The company held its 21st temporary meeting of the 8th Supervisory Board on May 21, 2025, where all three attending supervisors unanimously approved the proposal to open a special account for temporarily supplementing working capital with idle raised funds [1][2] - The company plans to use up to 181 million yuan of idle raised funds to temporarily supplement its working capital, ensuring compliance with regulatory requirements and protecting investors' rights [2] Group 1 - The meeting was legally valid with three supervisors present, meeting the required quorum [1] - The proposal to open a special account for the management of idle raised funds was passed with a unanimous vote of 3 in favor [1][2] - The company will sign a regulatory agreement with the sponsoring institution and the bank to oversee the storage and use of the raised funds [2]

东兴证券股份有限公司 关于中源协和细胞基因工程股份有限公司 使用闲置募集资金暂时补充流动资金的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"独立财务顾问"）作为 中源协和细胞基因工程股份有限公司（以下简称"中源协和"、 "上市公司"、 "公 司"）发行股份及支付现金购买资产并募集配套资金暨关联交易的独立财务顾问， 根据《上市公司募集资金监管规则（〔2025〕10 号）》 《上海证券交易所上市公司 自律监管指引第 1 号——规范运作（2023 年 12 月修订）》 《上海证券交易所股票 上市规则（2024 年 4 月修订）》《上市公司重大资产重组管理办法》等法律、法 规及规范性文件的规定，对于中源协和使用闲置募集资金暂时补充流动资金事项 进行了核查，并发表如下意见： 一、募集资金基本情况 根据中国证券监督管理委员会《关于核准中源协和细胞基因工程股份有限公 司向王晓鸽等发行股份购买资产并募集配套资金的批复》（证监许可20181180 号）核准文件，公司本次实际非公开发行人民币普通股 27,815,801 股，发行价格 为 16.07 元，募集资金总额为 446,999,922.07 元，扣除相关发行费用 ...

Group 1 - The company held the fifth meeting of the sixth supervisory board, which was conducted via email notification to all supervisors, ensuring compliance with relevant laws and regulations [1][2] - The supervisory board approved the proposal to temporarily use 300 million yuan of idle raised funds to supplement the company's working capital, emphasizing that this decision aligns with the company's development strategy and long-term planning [1][2] - The board confirmed that the use of idle funds would not harm the interests of the company and its shareholders, and the decision-making process adhered to legal and regulatory requirements [1][2] Group 2 - The voting results for the proposal were 3 votes in favor, with no votes against or abstentions, indicating unanimous support from the supervisory board [2] - The company disclosed the details of the proposal on the same day through the official website, ensuring transparency [2] - The resolution from the supervisory board meeting is available for review as a formal document [2]